$3.48 0.00 (0.00%)

Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI)

Maravai LifeSciences Holdings, Inc. Class A (MRVI) is a biotechnology company that provides essential products and technologies used in life sciences research, vaccine development, and diagnostics. The company specializes in the production of nucleic acid-based reagents, including mRNA, for pharmaceutical and research applications. Maravai focuses on supporting the global healthcare industry through its innovative solutions and scalable manufacturing capabilities.

🚫 Maravai LifeSciences Holdings, Inc. Class A Common Stock does not pay dividends

Company News

MARAVAI INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire Inc. • Bragar Eagel & Squire, P.C. • July 22, 2025

Maravai LifeSciences is under investigation for potential financial reporting irregularities, including revenue recognition errors and potential goodwill impairment, which led to a significant stock price drop.

MRVI Investors Reminded of Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Benzinga • Prnewswire • May 5, 2025

Investors who purchased Maravai LifeSciences Holdings, Inc. securities between August 7, 2024 and February 24, 2025 are encouraged to join a class action lawsuit against the company for alleged securities fraud violations.

3 Struggling Stocks Down More Than 50% This Year That Look Cheap But Come With Plenty of Risk
The Motley Fool • The Motley Fool • March 16, 2025

Three stocks that have dropped over 50% this year - SoundHound AI, Maravai LifeSciences, and Victoria's Secret - are struggling and may not be worth buying despite their discounted valuations due to uncertain futures and continued challenges.

SOUNSOUNWVSCO
Maravai (MRVI) Advances in RNA Research With New Collaboration
Zacks Investment Research • Zacks Equity Research • May 17, 2024

Per Maravai LifeSciences (MRVI) management, this development by TriLink is set to advance nucleic acid-based therapies.

RMDMEDPEHC
Investors have been scared out of this group of stocks, says fund manager, who offers five ideas for the rebound to come.
MarketWatch • MarketWatch • March 16, 2022

Risk-averse investors have been shunning small-cap stocks, but look for the clouds to clear soon over this asset class, says a fund manager at Artemis.

COMPTECHPLNTPOOLBABAJD